|Articles|February 11, 2009
Lucentis vs PDT: which is more cost-effective?
Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration
Advertisement
Please click
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Johnson & Johnson to acquire Ollin Biosciences in deal worth up to $3.3 billion
2
Q&A: What the FDA’s class-wide NAION warning on GLP-1s means for eye care
3
Dazodalibep data put Sjögren screening in focus for ophthalmologists
4
Q&A: Caroline R. Baumal, MD, from academic retina to the C-suite and back | Eichenbaum Acorns
5









